A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

计划入组 152 人 · 首次发布于 2016 年 7 月 28 日

Improved Factor VIII Inhibitor Evaluation

首次发布于 2016 年 4 月 1 日

The OCT SORT-OUT VIII Study

计划入组 160 人 · 首次发布于 2014 年 10 月 1 日

Bisindolylmaleimide VIII

C₂₄H₂₂N₄O₂

Recombinant factor VIII liposomal (Opperbas/Omri)

human factor VIII

ProQR Therapeutics VIII B.V.

Netherlands

HUALAN BIOLOGICAL ENGINEERING. INC.

VIIV HEALTHCARE COMPANY

United States

Graham: PDUFA VIII Reflects 'America First' Principles

FDA Initiates PDUFA VIII Negotiations with Industry Leaders, Emphasizing America First Approach

FDA Initiates PDUFA VIII Reauthorization Process with Public Meeting and Assessment Report